Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).
Case Reports Show an Association Between Immune Checkpoint Inhibitors and Risk for Rheumatologic DisordersJuly 11, 2016
A small number of patients with cancer treated with immune checkpoint inhibitors may have higher-than-usual risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a case report on 13 patients has shown.
Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
An international study demonstrated that ipilimumab improves the relapse-free survival of patients with advanced stage melanoma who are rendered free of disease surgically but at high risk for relapse.
The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.
Adjuvant ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but is also associated with a high rate of adverse events.
Almost half of patients with blood cancer who had relapsed following allogeneic stem cell transplantation benefitted from treatment with the immune checkpoint blocker ipilimumab.
Pairing ipilimumab with sargramostim gives patients about five extra months survival time for patients with advanced melanoma, researchers report.
Among patients with advanced melanoma, presence of higher levels of the protein VEGF in blood was associated with poor response to treatment with the immunotherapy ipilimumab.
High pretreatment VEGF levels have been linked to lower survival after ipilimumab treatment.
Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma
A new study suggests radiotherapy may hold clinical promise for the control of local lymph node bed recurrence of malignant melanoma.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|